Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays

Author:

Ducret Axel1,Ackaert Chloé2,Bessa Juliana1,Bunce Campbell3,Hickling Timothy1,Jawa Vibha4,Kroenke Mark A.5,Lamberth Kasper6,Manin Anaïs3,Penny Hweixian L.5,Smith Noel7,Terszowski Grzegorz8,Tourdot Sophie9,Spindeldreher Sebastian10ORCID

Affiliation:

1. Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland

2. ImmunXperts SA (A Nexelis Group Company), Gosselies, Belgium

3. Abzena, Babraham Research Campus, Cambridge, UK

4. Biotherapeutics and Bioanalysis Non-Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA

5. Clinical Immunology-Translational Medicine, Amgen Inc, Thousand Oaks, CA, USA

6. Analysis & Characterisation, Global Research Technologies, Novo Nordisk A/S, Måløv, Denmark

7. Lonza Biologics, Chesterford Research Park, Saffron Walden, UK

8. Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland

9. BioMedicine Design, Pfizer Inc, Andover, MA, USA

10. Integrated Biologix GmbH, Basel, Switzerland

Funder

no funding

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3